• Explore /
  • Poster
  • / Activation of the AKT pathway and outcomes in patients (pts) treated with or without ipatasertib (ipat) in metastatic castration-resistant prostate cancer (mCRPC): Next-generation sequencing (NGS) data from the phase III IPATential150 trial.

Activation of the AKT pathway and outcomes in patients (pts) treated with or without ipatasertib (ipat) in metastatic castration-resistant prostate cancer (mCRPC): Next-generation sequencing (NGS) data from the phase III IPATential150 trial.

Abstract Video & Slides Poster

Authors

null

Christopher Sweeney

Dana-Farber Cancer Institute, Boston, MA

Christopher Sweeney , Kim N. Chi , Sergio Bracarda , Cora N. Sternberg , David Olmos , Shahneen Sandhu , Christophe Massard , Nobuaki Matsubara , Malgorzata Nowicka , Nives Selak Bienz , Fanny Schenkel , Geng Chen , Matthew J. Wongchenko , Josep Garcia , Johann S. De Bono

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary Cancer—Prostate, Testicular, and Penile

Track

Genitourinary Cancer—Prostate, Testicular, and Penile

Sub Track

Prostate Cancer– Advanced/Castrate-Resistant

Clinical Trial Registration Number

NCT03072238

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 5056)

DOI

10.1200/JCO.2022.40.16_suppl.5056

Abstract #

5056

Poster Bd #

239

Abstract Disclosures

Similar Posters

First Author: Simon J. Crabb

First Author: Johann S. De Bono

First Author: Daniel Peter Petrylak

First Author: Sumit Kumar Subudhi